Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 808
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479402/808-10-50-1

License Agreements (Details) $ in Millions	1 Months Ended	3 Months Ended
License Agreements (Details) $ in Millions	Oct. 31, 2025 USD ($) Milestone shares	Mar. 31, 2026 USD ($)	Mar. 31, 2025 USD ($)	Jan. 31, 2025 USD ($)	May 31, 2021 USD ($)	Oct. 31, 2020 USD ($)
2020 Xencor Agreement
Nature of Business
Agreement transaction price		$ 0.0	$ 0.0
2021 Xencor Agreement
Nature of Business
Regulatory milestone payments					$ 75.0
Sales milestone payments					385.0
License and option agreements, food and drug administration market authorization payable					10.0
License and option agreements, food and drug administration market approval payable					$ 20.0
Viridian Agreement
Nature of Business
Sales milestone payments						$ 21.0
Contract manufacturing organization costs recognized		0.0	0.0
Reimbursable costs			$ 0.1
Development milestone expense payable				$ 21.0
InnoCare Pharma Inc
Nature of Business
Non-refundable cash payment	$ 35.0
Number of shares agreed to be issued \| shares	5,000,000
Amount of contingent payment payable upon on occurrence of specified events	$ 25.0
Number of shares agreed to be issued upon on occurrence of specified events \| shares	2,000,000
Term milestone payments	$ 20.0
Number Of Antibody Product Candidates \| Milestone	2
Future regulatory and commercial milestones payable	$ 723.0
Development, regulatory and commercial milestones payable	656.0
Regulatory milestones payable	$ 20.0
Contract manufacturing organization costs recognized		1.2
Reimbursable costs		$ 0.8